FDA Panel to Review Heart Contractility Booster, Renal Denervation
Devices for HFrEF, hypertension to be discussed over 2 days
WASHINGTON -- Cardiac contractility modulation (CCM) therapy and renal denervation will get an airing before a FDA advisory committee panel over 2 days starting Tuesday.